相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment
Laisheng Luo et al.
DIGESTIVE DISEASES AND SCIENCES (2020)
Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
Sho Suzuki et al.
GUT (2020)
Efficacy of Vonoprazan for Helicobacter pylori Eradication
Shu Kiyotoki et al.
INTERNAL MEDICINE (2020)
Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for Helicobacter pylori: A meta-analysis
Bo Li et al.
MICROBIAL PATHOGENESIS (2020)
Searching for an optimal therapy forH pylorieradication: High-dose proton-pump inhibitor dual therapy with amoxicillin vs. standard triple therapy for 14 days
Alex Hwong-Ruey Leow et al.
HELICOBACTER (2020)
Analysis of fitness costs associated with metronidazole and amoxicillin resistance inHelicobacter pylori
Ian H. Windham et al.
HELICOBACTER (2020)
Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy
Ravishankar M. Ram et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial
Wei-Chen Tai et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment A systematic review and meta-analysis
Xue Yang et al.
MEDICINE (2019)
High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial
Lou Yu et al.
HELICOBACTER (2019)
Helicobacter pylori resistance to current therapies
Sinead M. Smith et al.
CURRENT OPINION IN GASTROENTEROLOGY (2019)
Vonoprazan-Based Triple-Therapy Could Improve Efficacy of the Tailored Therapy of Helicobacter pylori Infection
Tetsuya Shinmura et al.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES (2019)
Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori
Jing Yang et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)
Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance
Xiaohua Long et al.
HELICOBACTER (2018)
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report
P. Malfertheiner et al.
GUT (2017)
In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker
Hitomi Yamasaki et al.
XENOBIOTICA (2017)
Optimized high-dose amoxicillinuproton-pump inhibitor dual therapies fail to achieve high cure rates in China
Jia-Li Hu et al.
SAUDI JOURNAL OF GASTROENTEROLOGY (2017)
A Non-Inferiority Study: Modified Dual Therapy Consisting Higher Doses of Rabeprazole Is as Successful as Standard Quadruple Therapy in Eradication of Helicobacter pylori
Ferdane Sapmaz et al.
AMERICAN JOURNAL OF THERAPEUTICS (2017)
Review article: the global emergence of Helicobacter pylori antibiotic resistance
I. Thung et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication
Kai-feng Pan et al.
GUT (2016)
Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta-analysis
Cai Ping Gao et al.
JOURNAL OF DIGESTIVE DISEASES (2016)
Multicenter Study of Antibiotic Resistance Profile of H-pylori and Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chongqing, China
Ran Han et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2016)
High Dose Ilaprazole/Amoxicillin as First-Line Regimen for Helicobacter pylori Infection in Korea
WonGun Kwack et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2016)
High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection
Jyh-Chin Yang et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans
Seiji Shiota et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly
David Y. Graham et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2015)
Lack of association among TNF-α gene expression,-308 polymorphism (G > A) and virulence markers of Helicobacter pylori
Luanna Munhoz Zabaglia et al.
JOURNAL OF VENOMOUS ANIMALS AND TOXINS INCLUDING TROPICAL DISEASES (2015)
Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade A'' Success Rate for First-Line Helicobacter pylori Eradication
Wei-Chen Tai et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Effect of Dosing Schemes of Amoxicillin on Eradication Rates of Helicobacter pylori With Amoxicillin-Based Triple Therapy
Takahisa Furuta et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
New dual therapy for primary treatment of Helicobacter pylori infection: A prospective randomized study in Shanghai, China
Ling Ren et al.
JOURNAL OF DIGESTIVE DISEASES (2014)
Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype
M. Sugimoto et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea
Seung Young Kim et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report
Peter Malfertheiner et al.
GUT (2012)
Helicobacter Pylori in Developing Countries. World Gastroenterology Organisation Global Guideline
R. H. Hunt et al.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES (2011)
World Gastroenterology Organisation Global Guideline Helicobacter pylori in Developing Countries
[Anonymous]
JOURNAL OF CLINICAL GASTROENTEROLOGY (2011)
Helicobacter pylori treatment in the era of increasing antibiotic resistance
David Y. Graham et al.
GUT (2010)
Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States
David Y. Graham et al.
JOURNAL OF GASTROENTEROLOGY (2010)
Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism
Horng-Yuan Lou et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin
Jung-Hwan Oh et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage
Jung Mook Kang et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2008)
Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy
Naohito Shirai et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H-pylori
T. Furuta et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin
S. Miehlke et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects
YM Hu et al.
ACTA PHARMACOLOGICA SINICA (2005)
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities
XQ Li et al.
DRUG METABOLISM AND DISPOSITION (2004)
Review article: relationship between the metabolism and efficacy of proton pump inhibitors - focus on rabeprazole
J Horn
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status
M Sugimoto et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy
M Nakamura et al.
HELICOBACTER (2003)
A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin
S Miehlke et al.
HELICOBACTER (2003)
Esomeprazole - enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion
P Lindberg et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori
L Gatta et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH
N Shirai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19
T Furuta et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient
T Furuta et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
分享论文
